FIELD OF INVENTION
[001] The present disclosure in general is directed to the field of skin benefitting compositions, particularly relate to anti-aging compositions for skin aging.
BACKGROUND OF THE INVENTION
[002] Skin aging is a multifactorial phenomenon exhibited by fine lines and wrinkles. Cellular senescence has emerged as a potential contributor for aging skin. Cellular senescence is a process which refers to irreversible cell cycle arrest. Senescent cells get accumulated upon aging and acquire altered morphology with differentiated functions which critically affect the extracellular matrix (ECM), skin elasticity and integrity. Skin aging manifests in the form of fine lines and wrinkles on facial skin and other parts of the body. Literature reveals that decreased senescence levels lead to enhanced cellular activities, skin firmness and elasticity. [003] For example, US6955816 B2 discloses anti-aging skin care compositions comprising Vitamin Bl, Vitamin B5, Vitamin C, N-acetyl-cysteine and, optionally, lipoic acid for therapeutically or prophylactically treating the consequences of aging on the condition or appearance of the skin. FR2838340 Al discloses the use of an extract of brown seaweed Pelvetia canaliculata as active ingredient in cosmetic and dermatological compositions. PCT/US2008/006207 discloses a composition comprising a combination of Polygonum fagopyrum seed extract, Chlorella vulgaris extract, palmitoyl wheat protein hydrolysate, algae extract, and tripeptide for aiding in improving the firmness of the skin, lifting the skin, decreasing skin sagging, and decreasing visible signs of aging including one or more of wrinkles, fine lines, uneven skin tone and age spots.
[004] Although several compositions in the past have disclosed compositions to combat skin aging and to reduce the signs of skin aging, there are only a few compositions that aim to target specific contributors of skin aging. Thus, there is a need to address the multifaceted problem of skin aging in an effective and targeted manner. SUMMARY OF THE INVENTION
[005] In an aspect of the present disclosure, there is provided a composition comprising: a) camosine, or derivatives thereof; and b) Boswellia seratta extract, wherein camosine, or derivatives thereof to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1. [006] In an aspect of the present disclosure, there is provided a process for preparing a composition comprising: a) camosine, or derivatives thereof; and b) Boswellia seratta extract,

wherein carnosine, or derivatives thereof to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1, said process comprising: i) obtaining carnosine, or derivatives thereof; ii) obtaining the Boswellia seratta extract; and iii) contacting carnosine and the Boswellia seratta extract, to obtain the composition.
[007] In an aspect of the present disclosure, there is provided a method for reducing ageing-associated skin conditions, said method comprising: a) obtaining the composition comprising: i) carnosine, or derivatives thereof; and ii) Boswellia seratta extract, wherein carnosine, or derivatives thereof to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1; and b) contacting the composition to skin, for reducing ageing-associated skin conditions [008] These and other features, aspects, and advantages of the present subject matter will be better understood with reference to the following description and appended claims. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
[009] The following drawings form a part of the present specification and are included to further illustrate aspects of the present disclosure. The disclosure may be better understood by reference to the drawings in combination with the detailed description of the specific embodiments presented herein.
[0010] Figure 1 shows the High-Performance Liquid Chromatography (HPLC) chromatogram of Boswellia seratta extract, in accordance with an embodiment of the present disclosure. [0011] Figure 2 shows the effect of carnosine on the viability of human dermal fibroblast cells, at various concentrations, in accordance with an embodiment of the present disclosure. [0012] Figure 3 shows the effect of Boswellia seratta extract on the viability of human dermal fibroblast cells, at various concentrations, in accordance with an embodiment of the present disclosure.
[0013] Figure 4A, 4B, and 4C depict the effect of carnosine and Boswellia seratta extract, alone and in combination, at various concentrations on senescence associated beta galactosidase (SA-(3-gal) expression, in accordance with an embodiment of the present disclosure.
DETAILED DESCRIPTION OF THE INVENTION
[0014] Those skilled in the art will be aware that the present disclosure is subject to variations and modifications other than those specifically described. It is to be understood that the present disclosure includes all such variations and modifications. The disclosure also includes all such

steps, features, compositions, and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any or more of such steps or features.
Definitions
[0015] For convenience, before further description of the present disclosure, certain terms
employed in the specification, and examples are collected here. These definitions should be
read in the light of the remainder of the disclosure and understood as by a person of skill in the
art. The terms used herein have the meanings recognized and known to those of skill in the art,
however, for convenience and completeness, particular terms and their meanings are set forth
below.
[0016] The articles "a", "an" and "the" are used to refer to one or to more than one (i.e., to at
least one) of the grammatical object of the article.
[0017] The terms "comprise" and "comprising" are used in the inclusive, open sense, meaning
that additional elements may be included. It is not intended to be construed as "consists of
only".
[0018] Throughout this specification, unless the context requires otherwise the word
"comprise", and variations such as "comprises" and "comprising", will be understood to imply
the inclusion of a stated element or step or group of element or steps but not the exclusion of
any other element or step or group of element or steps.
[0019] The term "including" is used to mean "including but not limited to". "Including" and
"including but not limited to" are used interchangeably.
[0020] The terms "emollient", "emulsifier", "chelating agent", "preservative", "UV
stabilizer", "bioactive", "diluent", are well understood by a person skilled in the art.
[0021] The term "at least one" is used to mean one or more and thus includes individual
components as well as mixtures/combinations.
[0022] The term "derivative" include compounds that can arise or actually be synthesized from
a parent compound by replacement of one atom with another atom or group of atoms.
[0023] Ratios, concentrations, amounts, and other numerical data may be presented herein in
a range format. It is to be understood that such range format is used merely for convenience
and brevity and should be interpreted flexibly to include not only the numerical values
explicitly recited as the limits of the range, but also to include all the individual numerical
values or sub-ranges encompassed within that range as if each numerical value and sub-range
is explicitly recited. For example, a ratio ranges of about 1:1 to 45:1 should be interpreted to

include not only the explicitly recited limits of about 1:1 to about 45:1, but also to include sub¬ranges, such as 10:1, 30:1, and so forth, as well as individual amounts, including fractional amounts, within the specified ranges, such as 33.3:1, and 10.2:1, for example. [0024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference. [0025] The term "at least one" is used to mean one or more and thus includes individual components as well as mixtures/combinations.
[0026] The present disclosure is not to be limited in scope by the specific implementations described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions, and methods are clearly within the scope of the disclosure, as described herein.
[0027] Conventional methods to treat aging related skin conditions involve complex cosmetic procedures, such as face lift, injectable gel fillers, laser treatments, chemical peeling, which are expensive, painful, and would require several sessions with a cosmetologist before any visible results are observed. Although a number of cosmetics formulated these days involve the use of plant-based ingredients or herbal ingredients to combat skin aging or address skin aging related issues such as wrinkles, elasticity, and the like, the supposed activity of most of such conventional compositions is unsubstantiated. Since very few compositions aim to target specific contributors of skin aging, there is a need to address the multifaceted problem of skin aging in an effective and targeted manner. Therefore, the objective of the present disclosure is to provide for a composition that can effectively and selectively target senescent cells to effectively reduce aging associated conditions. Accordingly, the present disclosure provides for a composition comprising: a) camosine and b) Boswellia seratta extract; which when used in defined w/w ratios is effective for treating skin aging.
[0028] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1.
[0029] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine, or derivatives thereof; and b) Boswellia seratta extract, wherein carnosine, or derivatives thereof, to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1.

[0030] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein carnosine to the Boswellia seratta extract has a weight ratio in a
range of 2:1 to 20:1.
[0031] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 20:1.
[0032] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein carnosine to the Boswellia seratta extract has a weight ratio in a
range of 2:1 to 10:1.
[0033] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 10:1.
[0034] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio of 5:1.
[0035] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein carnosine has a weight percentage in a range of 0.005-0.1% with
respect to the composition. In another embodiment of the present disclosure, carnosine has a
weight percentage in a range of 0.006-0.05% with respect to the composition. In yet another
embodiment of the present disclosure, carnosine has a weight percentage of 0.05% with respect
to the composition.
[0036] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 1:1 to 45:1, and wherein carnosine has a weight
percentage in a range of 0.005-0.1% with respect to the composition.
[0037] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 20:1, and wherein carnosine has a weight
percentage in a range of 0.005-0.1% with respect to the composition.
[0038] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 10:1, and wherein carnosine has a weight
percentage in a range of 0.005-0.1% with respect to the composition.

[0039] In an embodiment of the present disclosure, there is provided a composition as described herein, wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition. In another embodiment of the present disclosure, wherein the Boswellia seratta extract has a weight percentage in a range of 0.006-0.013% with respect to the composition. In yet another embodiment of the present disclosure, Boswellia seratta extract has a weight percentage of 0.01% with respect to the composition. [0040] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1, and wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition. [0041] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 20:1, and wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition. [0042] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 10:1, and wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition. [0043] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1, and wherein carnosine has a weight percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition.
[0044] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 20:1, and wherein carnosine has a weight percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition.
[0045] In an embodiment of the present disclosure, there is provided a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 10:1, and wherein carnosine has a weight percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia

seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the
composition.
[0046] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 3:1 to 6:1, and wherein carnosine has a weight
percentage in a range of 0.006-0.05% with respect to the composition; and wherein the
Boswellia seratta extract has a weight percentage in a range of 0.006-0.013% with respect to
the composition.
[0047] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein the Boswellia seratta extract comprises boswellic acid having a
weight percentage in a range of 0.0025-0.007% with respect to the extract. In another
embodiment of the present disclosure, the boswellic acid has a weight percentage in a range of
0.003-0.004% with respect to the extract.
[0048] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 1:1 to 45:1 and wherein the Boswellia seratta
extract comprises boswellic acid having a weight percentage in a range of 0.0025-0.007% with
respect to the extract.
[0049] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 1:1 to 45:1, and wherein carnosine has a weight
percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia
seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the
composition; and wherein the Boswellia seratta extract comprises boswellic acid having a
weight percentage in a range of 0.0025-0.007% with respect to the extract.
[0050] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 3:1 to 6:1, and wherein carnosine has a weight
percentage in a range of 0.006-0.05% with respect to the composition; and wherein the
Boswellia seratta extract has a weight percentage in a range of 0.006-0.013% with respect to
the composition, and wherein the Boswellia seratta extract comprises boswellic acid having a
weight percentage in a range of 0.003-0.004% with respect to the extract.
[0051] In an embodiment of the present disclosure, there is provided a process for preparing a
composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to

the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1, said process comprising: i) obtaining carnosine; ii) obtaining the Boswellia seratta extract; and iii) contacting carnosine and the Boswellia seratta extract, to obtain the composition. [0052] In an embodiment of the present disclosure, there is provided a process for preparing a composition comprising: a) carnosine, or derivatives thereof; and b) Boswellia seratta extract, wherein carnosine, or derivatives thereof, to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1, said process comprising: i) obtaining carnosine, or derivatives thereof; ii) obtaining the Boswellia seratta extract; and iii) contacting carnosine, or derivatives thereof, and the Boswellia seratta extract, to obtain the composition.
[0053] In an embodiment of the present disclosure, there is provided a process for preparing a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 20:1, said process comprising: i) obtaining carnosine; ii) obtaining the Boswellia seratta extract; and iii) contacting carnosine and the Boswellia seratta extract, to obtain the composition. [0054] In an embodiment of the present disclosure, there is provided a process for preparing a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 10:1, said process comprising: i) obtaining carnosine; ii) obtaining the Boswellia seratta extract; and iii) contacting carnosine and the Boswellia seratta extract, to obtain the composition. [0055] In an embodiment of the present disclosure, there is provided a process for preparing a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1, and wherein carnosine has a weight percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia seratta extract comprises boswellic acid having a weight percentage in a range of 0.0025-0.007% with respect to the extract; said process comprising: i) obtaining carnosine; ii) obtaining the Boswellia seratta extract; and iii) contacting carnosine and the Boswellia seratta extract, to obtain the composition. [0056] In an embodiment of the present disclosure, there is provided a process for preparing a composition comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia seratta extract has a weight ratio in a range of 3:1 to 6:1, and wherein carnosine has a weight percentage in a range of 0.006-0.05% with respect to the composition; and wherein the Boswellia seratta extract has a weight percentage in a range of 0.006-0.013% with respect to the composition, and wherein the Boswellia seratta extract comprises boswellic acid having

a weight percentage in a range of 0.003-0.004% with respect to the extract; said process
comprising: i) obtaining carnosine; ii) obtaining the Boswellia seratta extract; and iii)
contacting carnosine and the Boswellia seratta extract, to obtain the composition.
[0057] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein the composition decreases production of senescence associated beta
galactosidase.
[0058] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 1:1 to 45:1, and wherein the composition
decreases production of senescence associated beta galactosidase.
[0059] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 20:1, and wherein the composition
decreases production of senescence associated beta galactosidase.
[0060] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 10:1, and wherein the composition
decreases production of senescence associated beta galactosidase.
[0061] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 1:1 to 45:1, and wherein carnosine has a weight
percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia
seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the
composition; and wherein the Boswellia seratta extract comprises boswellic acid having a
weight percentage in a range of 0.0025-0.007% with respect to the extract; and wherein the
composition decreases production of senescence associated beta galactosidase.
[0062] In an embodiment of the present disclosure, there is provided a composition
comprising: a) carnosine; and b) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 3:1 to 6:1, and wherein carnosine has a weight
percentage in a range of 0.006-0.05% with respect to the composition; and wherein the
Boswellia seratta extract has a weight percentage in a range of 0.006-0.013% with respect to
the composition, and wherein the Boswellia seratta extract comprises boswellic acid having a
weight percentage in a range of 0.003-0.004% with respect to the extract; and wherein the
composition decreases production of senescence associated beta galactosidase.

[0063] In an embodiment of the present disclosure, there is provided a method for reducing
ageing-associated skin conditions, said method comprising: a) obtaining the composition
comprising i) carnosine; and ii) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 1:1 to 45:1; and b) contacting the composition
to skin, for reducing ageing-associated skin conditions.
[0064] In an embodiment of the present disclosure, there is provided a method for reducing
ageing-associated skin conditions, said method comprising: a) obtaining the composition
comprising i) carnosine; and ii) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 20:1; and b) contacting the composition
to skin, for reducing ageing-associated skin conditions.
[0065] In an embodiment of the present disclosure, there is provided a method for reducing
ageing-associated skin conditions, said method comprising: a) obtaining the composition
comprising i) carnosine; and ii) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 2:1 to 10:1; and b) contacting the composition
to skin, for reducing ageing-associated skin conditions.
[0066] In an embodiment of the present disclosure, there is provided a method for reducing
ageing-associated skin conditions, said method comprising: a) obtaining the composition
comprising i) carnosine; and ii) Boswellia seratta extract, wherein carnosine to the Boswellia
seratta extract has a weight ratio in a range of 1:1 to 45:1; and wherein carnosine has a weight
percentage in a range of 0.005-0.1% with respect to the composition; and wherein the Boswellia
seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the
composition; and wherein the Boswellia seratta extract comprises boswellic acid having a
weight percentage in a range of 0.0025-0.007% with respect to the extract, and b) contacting
the composition to skin, for reducing ageing-associated skin conditions.
[0067] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition can be for topical application.
[0068] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition can be in the form of an aerosol.
[0069] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition can be in the form of a lotion.
[0070] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition can be in form of an oil.
[0071] In an embodiment of the present disclosure, there is provided a composition as
described herein, wherein said composition can be in the form of a serum.

[0072] Although the subject matter has been described with reference to specific embodiments, this description is not meant to be construed in a limiting sense. Various modifications of the disclosed embodiments, as well as alternate embodiments of the subject matter, will become apparent to persons skilled in the art upon reference to the description of the subject matter. It is therefore contemplated that such modifications can be made without departing from the spirit or scope of the present subject matter as defined. EXAMPLES
[0073] The working as well as non-working examples of the present disclosure would now be illustrated. These examples are neither restrictive nor intended to be limiting to the scope of the present invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice of the disclosed methods and compositions, the exemplary methods, devices and materials are described herein. It is to be understood that this disclosure is not limited to particular methods, and experimental conditions described, as such methods and conditions may vary.
[0074] Conventionally used cosmetic compositions to address skin aging or aging associated skin conditions such as wrinkles, elasticity, and the like., involve the use of synthetic chemicals which are toxic and not environmentally friendly. Also, these synthetics may not be suitable to all skin types, and may cause several side-effects such as rashness, irritation, and inflammation of the skin. Although herbal alternatives are being increasingly used as desirable alternative, the supposed activity or the target of most of such conventional compositions is unsubstantiated. Accordingly, the present disclosure provides for a composition comprising: a) camosine and b) Boswellia seratta extract; which when used in defined w/w ratios selectively target senescent cells to effectively reduce aging associated conditions. Example 1: Materials and methods
[0075] Camosine, commercially purchased as dragosine, (product no. 844033) was procured from Symrise; Boswellia Seratta procured from Amrutha herbals; Human Dermal Fibroblast (HDF) cells were procured from Lonza; fibroblast basal medium was procured from Invitrogen; cellular senescence assay kit was procured from Cell Biolabs; and 10X phosphate buffered saline (PBS) from Sigma.
[0076] In order to determine the enzymatic levels of senescence associated with beta galactosidase (SA-(3-gal) expression in a co-culture model, HDF cells were seeded in 96- well plates and incubated in 5% CO2 incubator for a period of 24 hours. Post 24 hours, adherent

HDF cells were exposed to lOOuM hydrogen peroxide (H2O2) for 3hours, followed by
treatment with carnosine and Boswellia seratta extract at different concentrations, alone and in
combination ratios, in serum free fibroblast basal medium for 24 hrs. Post incubation with
actives, i.e., 48 hours, the cells were washed twice with IX PBS. Cell lysis and processing was
performed as perthe manufacturer's protocol (Cell Biolabs, Campisi, J. (2000)//? Vivo 14,183-
188; Dimri, G. P et al. (1995) Proc. Natl. Acad. Sci. USA 92:9363-9367) to estimate the
enzymatic levels of senescence associated with beta galactosidase (SA-(3-gal) expression.
Example 2: High-Performance Liquid Chromatography (HPLC) analysis of Boswellia
seratta extract
[0077] Figure 2 depicts a HPLC chromatogram of Boswellia seratta extract. The operating
conditions are as provided under:
Column: C-18
Mobile phase: 0.1% v/v phosphoric acid in water and acetonitrile
Flow rate: 2ml/minute
Signal wavelength for detection: 201nm and 248nm.
Sharp peaks observed between 6-8 minutes (around 6.8 minutes) correspond to boswellic
acid. Analysis revealed that the total percentage of boswellic acid in the Boswellia seratta
extract was 0.0035%.
Example 3: Cytotoxicity of carnosine and Boswellia seratta extract
[0078] Figure 2 and 3 depicts the cytotoxic effects of different concentrations of carnosine
and Boswellia seratta extract respectively on HDF. According to Figure 2, carnosine did not
show any cytotoxic effect across the range of concentration tested (0.05% - 0.006%) thus
confirming that a concentration of 0.05% can be employed safely for the composition. 100%
viability on exposure of HDF to carnosine was observed at concentrations beyond 0.05%. Since
0.05% of carnosine was found to be non-toxic to cells, this concentration was used for further
experimentation.
[0079] According to Figure 3, Boswellia seratta extract at a concentration of 0.0013% and
0.006% did not show any cytotoxic effect. 100% cell viability was observed at these
concentrations. Since 0.0013% of Boswellia seratta extract was found to be non-toxic to cells,
this concentration was used for further experimentation.
Example 4: Effect of carnosine and Boswellia seratta extract, alone and in combination
on SA-P-gal expression
[0080] 0.05% of carnosine and 0.01% of Boswellia seratta extract were tested individually
and in combination to determine the effect on SA-P-gal expression. The protocol followed for

the experiment was same as mentioned in Example 1. The results of the assay are presented in Figure 4A. When the individual actives were tested individually at a concentration of 0.05% of carnosine, and 0.01% of Boswellia seratta extract, a percentage in increase in SA-(3-gal expression was observed, in comparison the control for carnosine; and a marginal decrease, by about 2%, in expression of SA-(3-gal, responsible for cellular senescence, was observed with Boswellia seratta extract. However, a remarkable decrease of about 15% was observed when the actives were tested at the same concentrations but in combination [0.05% of carnosine, and 0.01% of Boswellia seratta extract]. A synergistic decrease in SA-(3-gal protein expression levels responsible for cellular senescence, was observed at the said combination, thereby enhancing cellular activities in aging skin.
[0081] The experiment was further repeated with varying concentrations of carnosine and Boswellia seratta extract, at different w/w ratio's, and the results are herewith presented in Figure 4B and Figure 4C. From Figure 4B, it can be observed that carnosine at 0.5% concentration resulted in 14% increase in SA-(3-gal protein expression, in comparison to the control; and Boswellia seratta extract at a concentration of 0.01% resulted in 2% decrease in SA-(3-gal protein expression, in comparison to the control. No synergistic effect was observed when a combination of carnosine at 0.5% and Boswellia seratta extract at 0.01% concentration with respect to individual actives, on SA-(3-gal protein expression. Similar results were obtained with 0.005% of carnosine, and 0.01% of Boswellia seratta extract, the results of which are presented in Figure 4C. The results presented in Figure 4C indicate that the combination of carnosine at 0.005% and Boswellia seratta extract at 0.01% concentration do not decrease SA¬P-gal protein expression with respect to individual actives. It can thus be inferred that a mere admixture of the two actives does not result in a synergistic decrease in SA-(3-gal protein expression, and therefore this combination of carnosine and Boswellia seratta extract cannot be arrived at without undue experimentation.
[0082] Thus, the present disclosure provides a novel and synergistic composition of carnosine and Boswellia seratta extract, which exhibits a synergistic decrease in SA-(3-gal protein expression at a 5:1 w/w ratio of carnosine and Boswellia seratta extract. This combination can thus aid in the inhibition of skin aging process. This apparent synergism of said combination is not readily apparent at all concentration combinations (as discussed previously), suggesting that the results are not a result of mere admixture of the two or routine in nature Advantages gained in the example illustrative process in this subject matter [0083] The present disclosure provides for a composition comprising: a) carnosine; and b) Boswellia seratta extract, which when used in defined w/w ratios can selectively target

senescent cells for effective treatment of skin aging and aging associated skin conditions. The compositions of the present disclosure can be effectively used for topical application in the form of creams and lotions, within the comfort of home, without having to go through tedious, expensive cosmetic procedures. Also, the compositions of the present disclosure are of plant-origin, are hence non-toxic and environmentally friendly, thereby overcoming the drawbacks associated with synthetic chemicals.

I/We Claim;
1. A composition comprising:
a) camosine, or derivatives thereof; and
b) Boswellia seratta extract,
wherein carnosine, or derivatives thereof, to the Boswellia seratta extract has a weight ratio in a range of 1:1 to 45:1.
2. The composition as claimed in claim 1, wherein carnosine, or derivatives thereof, to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 20:1.
3. The composition as claimed in claim 1, wherein carnosine, or derivatives thereof, to the Boswellia seratta extract has a weight ratio in a range of 2:1 to 10:1.
4. The composition as claimed in claim 1, wherein carnosine, or derivatives thereof, has a weight percentage in a range of 0.005-0.1% with respect to the composition.
5. The composition as claimed in claim 1, wherein the Boswellia seratta extract has a weight percentage in a range of 0.005-0.1% with respect to the composition.
6. The composition as claimed in claim 1, wherein the Boswellia seratta extract comprises boswellic acid having a weight percentage in a range of 0.0025-0.007% with respect to the extract.
7. A process for preparing the composition as claimed in claim 1, said process comprising:

a) obtaining carnosine, or derivatives thereof;
b) obtaining the Boswellia seratta extract; and
c) contacting carnosine, or derivatives thereof, and the Boswellia seratta extract, to obtain the composition.

8. The composition as claimed in any one of the claims 1-6, wherein the composition decreases production of senescence associated beta galactosidase.
9. A method for reducing ageing-associated skin conditions, said method comprising:

a) obtaining the composition as claimed in any one of the claims 1-6; and
b) contacting the composition to skin,
for reducing ageing-associated skin conditions.